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Abstract  
Objectives 
To compare retinal thickness before and after treatment with the fluocinolone 
acetonide (FAc) 190 µg intravitreal implant in people with diabetic macular oedema 
(DMO) using data from the ILUVIEN Clinical Evidence study in the United Kingdom 
(ICE-UK). 
Methods 
For this retrospective cohort study, data on people attending any one of 13 
participating ophthalmology departments and treated with FAc intravitreal implant 
between 1 April 2013 and 15 April 2015 were collected for 12 months prior to and at 
least 12 months after implantation. Cross sectional and longitudinal patterns of 
central foveal thickness (CFT) were compared before and after FAc implant. 
Results 
There were 208 people contributed data from 233 individual eyes treated with the 
FAc implant. Mean age was 68.1 years and 62% were male. Median (interquartile 
range) CFT decreased from 462 µm (354–603 µm) at time of implant to 309 µm 
(222–433 µm) at 12 months post implant (p<0.001). Over the same period, a 
reduction of ≥10%, ≥25% and ≥50% in CFT was observed in 113 (65%), 87 (50%) and 
37 (21%) treated eyes, respectively. Eyes with a CFT of ≥400 µm at the time of 
implant were significantly more likely to achieve a reduction in CFT of ≥10%, ≥25% 
and ≥50% at 12 months (all p<0.001) compared with eyes with a CFT of <400 µm at 
implant. Both retinal thickness and changes in retinal thickness were loosely 
correlated with visual acuity. 
Conclusion 
A marked reduction in retinal thickness was observed in people following FAc 
intravitreal implant for DMO. The response was related to the degree of retinal 
thickness prior to treatment.
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Introduction 
The typical thickness of the retina in people with healthy eyes is around 200 m, 
which can vary slightly according to the part of the retina measured and type of 
ocular coherence tomography (OCT) used, with separate studies having reported 
either no change or a small decrease in thickness with increasing age.1,2 Damage to 
the eye caused by conditions such as macular oedema or trauma can lead to 
abnormal fluid accumulation resulting in thickening of the retina. Along with other 
microvascular changes, thickening of the retina follows sustained periods of 
hyperglycaemia in people with diabetes. Although macular oedema does not always 
result in a deterioration in vision, disruption of the fovea can cause severe visual 
impairment.1  
The fluocinolone acetonide (FAc) 190 µg intravitreal implant was evaluated in the 
Fluocinolone Acetonide in Diabetic Macular Edema (FAME) study programme.3,4 
Continuous daily release of low levels of FAc from the implant has been found to 
result in a reduction in foveal thickness and oedema for up to three years.4  
Historically, laser photocoagulation was considered to be the treatment of choice for 
DMO due to favourable results from the Early Treatment Diabetic Retinopathy Study 
(ETDRS).5 The FAME study therefore evaluated FAc intravitreal implant in people 
with an inadequate response to retinal laser therapy. However, since the FAME 
study was conducted, several landmark trials have demonstrated that anti-vascular 
endothelial growth factor (anti-VEGF) therapy can lead to a significant improvement 
in vision in people with DMO,6–9 and anti-VEGF therapy is now generally considered 
to be the first-line therapy for this condition. Therefore, in Europe, FAc intravitreal 
implant is presently indicated for the management of chronic DMO only where an 
insufficient response has been achieved with first-line anti-VEGF therapy. The aim of 
the ILUVIEN Clinical Evidence Study in the UK (ICE-UK) was to assess the 
effectiveness of FAc intravitreal implant for DMO in real world clinical practice. The 
purpose of this study was specifically to evaluate retinal thickness 12 months before 
and after treatment with the FAc 190 µg intravitreal implant.  
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Methods 
Data Source 
The dataset and study methodology have been described in detail elsewhere.10 
Briefly, for this retrospective, multi-centre, hospital-based study, data were 
extracted from medical records for a representative cohort of people treated at 13 
participating hospitals in the UK and combined into a single dataset for the purpose 
of analysis. Data were generated from retrospective case reviews, pseudonymised 
and entered into an online data entry tool. The following data were collected at 
several time points within a pre-specified period: patient demographics, medical 
history, implant data, and data from multi-disciplinary and medication reviews.  
 
Ethical approval 
The lead clinician and Caldicott Guardian at each centre gave written approval for 
extraction of anonymised data. The study protocol was approved by the head of 
research governance at the lead clinical centre. This study was conducted in 
accordance with the Declaration of Helsinki and the UK Data Protection Act. 
 
Subjects 
Subjects were people with type 1 or type 2 diabetes treated with FAc 190 µg 
intravitreal implant for DMO in at least one eye at a participating site as part of their 
routine care between 1 April 2013 and 15 April 2015. A requirement was a minimum 
of 12 months’ history prior to implant. Those with a history of taking part in any 
other interventional study for DMO or who were lost to follow-up were excluded. 
The index date was defined as the date of first recorded FAc intravitreal implant into 
the study eye. The follow-up period was defined as 12 months post implant and 
subjects who received FAc intravitreal implant in both eyes were allowed to 
contribute both eyes to the study.  
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Outcomes 
The following clinical outcomes were investigated at 3, 6 and 12 months post index 
date: changes in central foveal thickness (CFT) and central subfield thickness (CST) 
and the proportion of treated eyes that demonstrated a 10%, 25% and 50% 
improvement in CFT or CST. The distribution of CFT and CST from 12 months prior to 
and 12 months post implant was also investigated. Due to the observational nature 
of this study, there was no restriction on the OCT machine type used to measure 
retinal thickness.  
 
Subgroups 
Results are presented overall and for two subgroups based on higher and lower CFT 
at implant (≥400 µm and <400 µm, respectively). Eyes with no recorded CFT 
measurement at baseline were excluded from the subgroup analyses. 
 
Statistical analysis 
Changes in retinal thickness were compared between implant and the 3, 6 and 12 
month time points using the non-parametric Wilcoxon signed ranks test. The 
proportion of people achieving a reduction in retinal thickness between implant at 
these time points was compared between subgroups using Fisher’s exact test. The 
proportion of people achieving a target retinal thickness was compared between 
implant and the 3, 6 and 12 month time points using McNemar’s test. Last 
observation carried forward was implemented to impute missing values in two 
stages: on or before index date and after index date.11  
Mean and median CFT and CST were calculated on a daily basis for the 12 months 
before and after FAc implant. In order to smooth the data, missing values for each 
day of this 24 month period were imputed using linear interpolation.11 As linear 
interpolation could not be used before the first recorded value or after the last 
recorded value, nearest observation carried forward and backwards was used to 
impute the remaining missing values. In order to investigate whether CFTs <200 µm 
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have a detrimental effect on vision, visual acuity (ETDRS letter score) in the 12 
months prior to and post FAc implant was investigated for study eyes with a CFT of 
<200 µm at baseline using the same methodology.  
The strength and direction of the association between pairs of visual acuity and CFT 
measurements recorded at FAc implant, 12 months post FAc implant and at any time 
in the 12 months prior to and post FAc implantation were measured using the 
Pearson’s correlation coefficient. Statistical analyses were carried out using IBM SPSS 
Statistics version 20.  
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Results 
Data were collected on 311 people, of whom 208 people contributing data from 233 
eyes treated with FAc intravitreal implant (study eyes) were eligible for inclusion in 
the study cohort. An attrition flow diagram has been previously presented.10 Of the 
233 study eyes, 208 were first eyes treated with the implant and 25 were a second 
treatment in the subject’s other eye.  
 
Patient demographics 
Of the 208 people treated with FAc intravitreal implant in any eye, 128 (62%) were 
male. The mean age was 68.1 years. 176 (85%) had type 2 diabetes (Table 1). Median 
(interquartile range, IQR) duration of diabetes was 18 (11–27) years. 63 eyes (27%) 
had a CFT of <400 µm at the time of implant and 128 (55%) eyes had a CFT of ≥400 
µm at the time of implant. 42 study eyes had no recorded CFT measurement within 
the 12 month period prior to implant and were therefore excluded from the 
subgroup analysis. 
207 treated eyes (89%) had a pseudophakic lens at the time of implant. Median 
(IQR) visual acuity at implant was 0.66 (0.48–1.00) LogMAR units (equivalent to 
median 52, IQR 35–61, ETDRS letters). CFT at implant was a mean (SD) of 482 m 
(186 m). Median (IQR) CST at the time of implant was 447 (352–587) µm. Median 
(IQR) numbers of macular laser treatments, steroid treatments and anti-VEGF 
injections prior to index date were 1.0 (0.0–3.0), 0.0 (0.0–1.0) and 5.0 (2.0–7.0), 
respectively. 
 
Central foveal thickness 
Not all subjects had relevant observations at all time points. Following multiple 
imputation of missing values and reporting only paired observations, the median 
(IQR) CFT decreased following implant at each time point: 472 µm (365–616 µm) at 
implant to 355 µm (254–474 µm) at 3 months (p<0.001), 464 µm (362–605 µm) at 
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implant to 331 µm (239–462 µm) at 6 months (p<0.001) and 462 µm (354–603 µm) 
at implant to 309 µm (222–433 µm) at 12 months (p<0.001; Table 2).  
A reduction of ≥10% in CFT from implant was observed in 76 (51%), 96 (57%) and 
113 (65%) treated eyes at 3 months, 6 months and 12 months post implant, 
respectively. A reduction of ≥25% and ≥50% in CFT from implant was observed in 61 
(41%) and 21 (14%) treated eyes at 3 months, 75 (44%) and 30 (18%) at 6 months 
and 87 (50%) and 37 (21%) at 12 months, respectively. When compared with eyes 
with a CFT of <400 µm at the time of implant, eyes with a CFT of ≥400 µm at implant 
were significantly more likely to achieve a reduction in CFT of ≥25% and ≥50% at 3 
months (p<0.001, p<0.001 and p=0.004, respectively), 6 months (all p<0.001) and 12 
months (all p<0.001).  
Mean CFT was higher in the 12 months prior to implant compared with the 12 
months after implant and tended to increase in the 3 months immediately prior to 
implant (Figure 1a). CFT continued to gradually decrease throughout the 12 months 
following implant.  
When compared with baseline, a steeper cumulative frequency curve was observed 
at 12 months follow-up, with more study eyes achieving lower CFTs at 12 months 
following FAc implant (Figure 2). However, the proportion of study eyes with a CFT 
of ≤150 µm was the same prior to and 12 months post FAc implant (2%). The 
distribution of study eyes by CFT category of <200 µm, ≥200 and <300 µm, ≥300 and 
<400 µm and ≥400 µm at FAc implant and 12 months post FAc implant is described 
in Figure 3a and b. Most study eyes had a CFT of ≥400 µm at the time of FAc 
implantation (66%). At 12 months post FAc implant, 51% of study eyes moved to a 
lower CFT category, 7% moved to a higher CFT category and 42% remained in the 
same category. CFT was <300 µm in 16% of eyes at implant and 47% of eyes at 12 
months post implant (p<0.001, Figure 2). For eyes with a CFT <400 µm at the time of 
implant, CFT was <300 µm in 47% of eyes at the time of FAc implant and 66% of eyes 
at 12 months (p=0.382). In those eyes with a CFT of ≥400 µm at the time of FAc 
implant, 38% achieved a CFT of <300 µm at 12 months post implant. 6% of eyes had 
a CFT of <200 µm at the time of FAc implant and 19% of eyes had a CFT of <200 µm 
at 12 months following FAc implant (p<0.001). Change in visual acuity in the 12 
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months prior to and post FAc implant are detailed in Figure 4 for these study eyes. 
For study eyes with a CFT of <200 µm at FAc implant, visual acuity was slightly higher 
in the 12 months post FAc implant than in the 12 months prior to FAc implant. 
Comparing the 12 months prior to and post FAc implant, a larger improvement in 
visual acuity was observed in study eyes with a CFT of >200 µm at FAc implant and a 
CFT of <200 µm at 12 months post FAc implant.  
At FAc implantation, Heidelberg SPECTRALIS OCT machine was used to measure 
retinal thickness in 61% of eyes with a recorded CFT; Topcon 3D OCT-2000 was used 
in 38% of eyes; and Topcon 3D OCT-1000 was used in 1% of eyes. The corresponding 
values were 56%, 41% and 3%, respectively, at 3 months; 58%, 38% and 3%, 
respectively, at 6 months; and 59%, 38% and 3%, respectively, at 12 months. Retinal 
thickness was measured using different OCT machine types at baseline and at 3, 6 
and 12 months post FAc implant in 5%, 7% and 7% of eyes, respectively. In study 
eyes, whose CFT was measured using a Heidelberg SPECTRALIS machine both prior 
to FAc implant and 12 months following implant, median CFT decreased from 492 
µm (IQR 388–647 µm) to 302 µm (210–421 µm, n=99). In study eyes where a Topcon 
3D OCT-2000 was used both at baseline and 12 months follow-up, median CFT 
decreased from 413 µm (IQR 323-514 µm) to 317 µm (293–436 µm, n=62). 
 
Correlation between central foveal thickness and visual acuity 
There was a statistically significant negative correlation between visual acuity (ETDRS 
letter score) and CFT at FAc implantation (Pearson’s correlation coefficient r=-0.311, 
p<0.001) and at 12 months post FAc implant (r=-0.250, p<0.001, Figure 5a and b). A 
statistically significant negative correlation between visual acuity and CFT was also 
observed when all pairs of CFT measurements and visual acuity measurements 
recorded between 12 months prior to FAc implant and 12 months post FAc implant 
were analysed (r=-0.259, p<0.001, Figure 5c). However, the variance in visual acuity 
accounted for by CFT was small (coefficient of determination R2=0.097 at FAc 
implant, R2=0.067 at 12 months post FAc implant and R2=0.067 for all measurements 
in the 12 months prior to and post FAc implant). Change in CFT and change in visual 
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acuity between FAc implant and 12 months post FAc implant were also significantly 
related (r=-0.285, p<0.001, R2=0.094, Figure 5d). 
 
Central subfield thickness 
Median (IQR) CST decreased from baseline at each time point: 448 µm (354–587) at 
baseline to 356 µm (276–453 µm) at 3 months (p<0.001), 448 µm (359–581 µm) at 
baseline to 337 µm (268–445 µm) at 6 months (p<0.001) and 446 µm (359–569 µm) 
at baseline to 318 µm (262–419 µm) at 12 months (p<0.001, Table 3).  
A reduction of ≥10% in CST was observed in 83 (54%), 103 (58%) and 118 (65%) 
treated eyes at 3 months, 6 months and 12 months post implant. A reduction of 
≥25% and ≥50% in CFT from implant was observed in 47 (30%) and 13 (8%) treated 
eyes at 3 months, 62 (35%) and 23 (13%) at 6 months, and 76 (42%) and 25 (14%) at 
12 months, respectively.  
Following linear interpolation of missing values (with nearest observation carried 
forward and backwards to impute missing values before the first recorded 
measurement and after the last recorded measurement), mean CST was higher in 
the 12 months prior to implant than in the 12 months post implant (Figure 1b). An 
increase in mean CST was observed in the four months prior to implant. CST 
continued to decrease gradually throughout the 12 month period following implant.  
  
11 
  
Discussion 
In the 12 months prior to the insertion of the FAc intravitreal implant, central retinal 
thickness continued to increase. Following implant, there was a marked reduction in 
the central retinal thickness. The onset of the beneficial changes in the morphology 
of the retina appeared to be both rapid and sustained for the period of this study. 
Response was based on CFT prior to treatment with the FAc intravitreal implant, 
being greater in those with a higher CFT (≥400 µm) at baseline and less in those eyes 
with a lower CFT (<400 µm) at baseline.  
Several types of OCT machine types were used to measure retinal thicknesses across 
the 13 participating ophthalmology centres. Retinal thickness measurements have 
been shown to vary depending on machine type, which is thought to be due to 
variation in the retinal segmentation algorithms.12 The same OCT machine in each 
unit was used to measure retinal thickness at baseline and the three follow-up time 
points in most study eyes.  
Whilst bearing in mind that retinal thinning due to cell loss can also be harmful,13 in 
the longer term, it has been reported that eyes that improve most in visual acuity, 
have the greatest decrease in retinal thickness.14 Nevertheless, the association 
between visual acuity and retinal thickness is still poorly understood.15,16 In this 
study, a significant negative association between visual acuity (ETDRS letter score) 
and CFT was observed. However, the variation in visual acuity explained by CFT was 
low. The Diabetic Retinopathy Clinical Research Network has previously investigated 
the relationship between retinal thickness and visual acuity before and after laser 
treatment in patients with DMO, and a moderate correlation between visual acuity 
and centre point thickness was observed (correlation coefficient of 0.52 at baseline 
and 0.49, 0.36 and 0.38 at 3.5, 8 and 12 months post laser photocoagulation). 
Furthermore, a correlation between change in visual acuity and change in centre 
point thickness was also reported (correlation coefficient of 0.44, 0.30 and 0.43 at 
3.5, 8 and 12 months post laser photocoagulation).17 However, the researchers also 
observed considerable variation in visual acuity for a particular level of retinal 
oedema.17  
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What is not a matter of conjecture is that any increase in retinal thickness from the 
norm represents physiological morbidity. Cataract surgery increases retinal 
thickness,18 and recovery in retinal thickness varies by the region of the retina.19 
However, central point thickness has been shown to recover relatively quickly 
following cataract surgery in people pre-treated with the FAc intravitreal implant.20 
PRP is reported to increase local inflammation resulting in effects such as localised 
cytokine release.21 In the later stages of diabetic eye diseases, multiple treatments 
are typically used together in complex patterns of treatment to salvage sight. Retinal 
thickness is thought to be an important, and objective measure of clinical outcome.14  
Anti-VEGF therapy is now considered to be the first-line treatment for DMO, and this 
class of drugs has been shown to be effective in reducing retinal thickness.6,22–27 The 
two licensed anti-VEGF products for DMO available in the UK—ranibizumab and 
aflibercept—have been recommended by NICE for the treatment of DMO in eyes 
with a central retinal thickness ≥400 µm, since both products have been determined 
to be cost-effective only in those eyes with this central retinal thickness.28,29 
However, the NICE recommendation for FAc intravitreal implant does not include 
any restrictions based on central retinal thickness.30 Laser therapy or intravitreal 
steroids (in eyes with a pseudophakic lens) are the only recommended treatment 
options in eyes with a central macular thickness of <400 µm. In this study, we 
examined changes in CST and CFT in subgroups based on baseline CFT of <400 µm 
and ≥400 µm. The change in CFT between implant and the end of the 12 month 
observation period was statistically significantly greater in those with a CFT of ≥400 
µm at the time of implant but not in those eyes with a CFT of <400 µm. Eyes with a 
smaller CFT at the time of FAc implant have less potential to improve. Sample size 
was relatively small in the CFT subgroups. 
A reduction in retinal thickness post FAc implant has also been observed in other 
studies. In the FAME study, baseline mean foveal thickness was 451 µm and 461 µm 
in the sham and low dose (0.2 µg/day) groups, respectively.4 At six months, the 
mean foveal thickness was 396 µm in the sham group and 318 µm in the 0.2 µg/day 
group.4 At 36 months, mean foveal thickness was 309 µm and 280 µm respectively.4 
Similar results were observed in this study, where median CFT in study eyes had 
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decreased from 464 µm at implant to 331 µm at 6 months. By 12 months, median 
CFT was 309 µm. In the largest published observational study to date, El-Ghrably and 
colleagues reported a mean reduction in central macular thickness of 126 μm at 12 
months following FAc implant.31 In line with the findings from this study, central 
macular thickness decreased rapidly after implant and this was sustained for the 12 
month follow-up period.31 Several other smaller observational studies have 
investigated the change in central retinal thickness following FAc intravitreal implant 
for DMO. In a retrospective study conducted by Elaraoud and colleagues, central 
retinal thickness was found to have decreased by a mean of 149 µm at three months 
post FAc implant.32 In this study, 7% of study eyes moved into a higher CFT category 
between baseline and 12 months post FAc implant. Elaraoud and colleagues also 
reported a worsening in CFT in 4 out of the 22 eyes included in their retrospective 
study at 3 months post implant.32 In a prospective, non-randomised, phase 4, pilot 
study, Figueira and colleagues observed a statistically significant decrease in CST 12 
months after FAc implant, and a rapid decrease in CST in the first week after 
implant.33 Rapid and sustained reductions in CST following FAc implant were also 
observed in a prospective study conducted by Massin and colleagues.34  
 
Strengths and limitations 
The strengths and limitations of the study have been described previously.10 As this 
is an observational study, several limitations are likely to apply including the 
misclassification of outcomes, effectiveness and safety. Outcomes were not 
measured at set times post index and were not consistently available across all 
participating centres for all the time points. Recall of participants to attend 
measurement may have led to differential misclassification and missing values. 
There were inconsistencies in the information recorded on cataract operations and 
lens status. Duration of DMO was not recorded. Analysis was restricted to 12 months 
follow-up post implant because available follow-up after this date varied from 
person to person.  
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First and second treated eyes from the same person were analysed as independent 
observations. However, second eyes may be more likely to be treated with FAc 
intravitreal implant if the patient had a positive response to treatment in the first 
eye. In addition, treatment of the second eye may be more likely to occur at certain 
treatment centres. Whilst minimising the elimination of individuals from the 
analysis, methods used to impute missing values have inherent limitations. Last 
observation carried forward can produce a biased estimate of treatment effect. 
However, as retinal thickness continued to improve over the duration of the period 
of follow-up, we believe that last observation carried forward will provide a 
conservative estimate for the effect of FAc on retinal thickness. 
 
Conclusions 
In our cohort of people with DMO, where 96% had a prior history of receiving anti-
VEGF injections, laser therapy and/or other intravitreal steroids, central retinal 
thickness increased in the 12 months prior to the insertion of the FAc intravitreal 
implant. Following treatment with the FAc intravitreal implant, a marked and 
sustained reduction in Central foveal thickness was observed in the 12 months 
following implant. A statistically significant negative correlation between central 
foveal thickness and visual acuity (ETDRS letters score) was also observed. However, 
the variance in visual acuity accounted for by central foveal thickness was low.  
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Tables and figures 
Table 1 | Baseline characteristics overall and by baseline central foveal thickness  
Parameter Overall By CFT at baseline 
<400 µm ≥400 µm 
Subjects, n 208 
 
53 (25%) 115 (55%) 
First eyes treated, n (%) 208 (89%) 53 (25%) 115 (55%) 
Second eyes treated, n (%) 25 (11%) 10 (40%) 13 (52%) 
All treated eyes, n (%) 233 
 
63 (27%) 128 (55%)        
Patient characteristics 
      
Age last clinic visit, mean (SD)a 68.1 (10.7) 68.2 (11.7) 67.7 (9.8) 
Males, n (%) 128 (62%) 36 (59%) 77 (66%) 
Type 2 diabetes, n (%) 176 (85%) 50 (82%) 99 (85%) 
Tablets 76 (43%) 18 (36%) 49 (49%) 
Insulin 43 (24%) 14 (28%) 21 (21%) 
Insulin plus tablets 57 (32%) 18 (36%) 29 (29%) 
Type 1 diabetes, n (%) 32 (15%) 11 (18%) 18 (15%) 
Tablets 0 (0%) 0 (0%) 0 (0%) 
Insulin 28 (88%) 10 (91%) 15 (83%) 
Insulin plus tablets 4 (13%) 1 (9%) 3 (17%) 
Number of years with diabetes, median 
(IQR)a 
18 (11–27) 18 (12–27) 18 (10–27) 
       
Eye characteristics 
      
Pseudophakic lens status, n (%)b 207 (89%) 53 (84%) 113 (88%) 
Visual acuity, LogMAR units 
      
n (%) 224 (96%) 63 (100%) 128 (100%) 
Median (IQR) 0.66 (0.48–1) 0.6 (0.3–0.8) 0.7 (0.5–1) 
Visual acuity, ETDRS letters       
n (%) 224 (96%) 63 (100%) 128 (100%) 
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Median (IQR) 52 (35–61) 55 (45–70) 50 (35–60) 
CST, µm 
      
n (%) 198 (85%) 58 
   
Median (IQR) 447 (352–587) 324 (281–371) 520 (438–627) 
CFT, µm 
      
n (%) 191 (82%) 63 (100%) 128 (100%) 
mean (SD) 482 (186) 285 (77) 579 (141) 
IOP, mmHg 
      
n (%) 185 (79%) 51 (81%) 102 (80%) 
Median (IQR), mmHg 15 (13–18) 16 (13–18) 15 (12–17) 
Prior macular laser treatments 
      
n (%) 146 (63%) 41 (65%) 81 (63%) 
Median (IQR) 1 (0–3) 1 (0–0) 1 (0–3) 
Prior anti–VEGF injections 
      
n (%) 191 (82%) 50 (79%) 107 (84%) 
Median (IQR) 5 (2–7) 4 (2–7) 5 (2–7) 
Prior ranibizumab injections 
      
n (%) 162 (70%) 44 (70%) 97 (76%) 
Median (IQR) 3 (0–6) 3 (0–6) 4 (1–6) 
Prior aflibercept injections 
      
n (%) 1 (0%) 1 (2%) 0 (0%) 
Median (IQR) 0 (0–0) 0 (0–0) 0 (0–0) 
Prior bevacizumab injections 
      
n (%) 74 (32%) 17 (27%) 29 (23%) 
Median (IQR) 0 (0–2) 0 (0–1) 0 (0–0) 
Prior steroid injections, 
      
n (%) 101 (43%) 27 (43%) 54 (42%) 
Median (IQR) 0 (0–1) 0 (0–1) 0 (0–1) 
Prior dexamethasone injections 
      
n (%) 17 (7%) 2 (3%) 4 (3%) 
Median (IQR) 0 (0–0) 0 (0–0) 0 (0–0) 
Prior triamcinolone injections 
      
n (%) 88 (38%) 25 (40%) 51 (40%) 
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Median (IQR) 0 (0–1) 0 (0–1) 0 (0–1) 
IOP-lowering medication, n (%) 44 (19%) 12 (19%) 24 (19%) 
Prostaglandin analogues, n (%) 26 (11%) 6 (10%) 15 (12%) 
Beta blockers, n (%) 17 (7%) 4 (6%) 11 (9%) 
Alpha agonists, n (%) 5 (2%) 2 (3%) 3 (2%) 
Carbonic anhydrase inhibitors, n (%) 11 (5%) 0 (0%) 7 (5%) 
Other, n (%) 8 (3%) 3 (5%) 5 (4%) 
CFT = central foveal thickness, SD = standard deviation, IQR = interquartile range, LogMAR = logarithm of the minimum angle of resolution, ETDRS = Early Treatment 
Diabetic Retinopathy Study, CST = central subfield thickness, CFT = central foveal thickness, IOP = intraocular pressure, VEGF = vascular endothelial growth factor 
a These are approximate estimates as it was not possible to determine the exact date on which these parameters were recorded in the dataset. 
b  Include operations carried out on day of implant (n=18). 
Although some of the characteristics relate to the individual and not the eye, each eye was analysed as an independent observation.
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Table 2 | Change in central foveal thickness  
 
N Baseline CFT(µm) Post-index CFT (µm) p-value ≥10% reduction 
in CFT 
≥25% reduction in 
CFT 
≥50% reduction in 
CFT 
  
Median (IQR) Median (IQR) 
 
3 months             
Overall 148 472 (365–616) 355 (254–474) <0.001 76 (51%) 61 (41%) 21 (14%) 
CFT subgroup 
      
<400 µm 47 302 (244–362) 282 (211–343) 0.453 14 (30%) 9 (19%) 1 (2%) 
≥400 µm 101 530 (462–662) 398 (273–515) <0.001 62 (61%) 52 (51%) 20 (20%) 
             
6 months             
Overall 169 464 (362–605) 331 (239–462) <0.001 96 (57%) 75 (44%) 30 (18%) 
CFT subgroup 
      
<400 µm 56 302 (233–358) 279 (210–357.5) 0.718 18 (32%) 11 (20%) 0 (0%) 
≥400 µm 113 531 (464–674) 388 (259–501) <0.001 78 (69%) 64 (57%) 30 (27%) 
             
12 months             
Overall 173 462 (354–603) 309 (222–433) <0.001 113 (65%) 87 (50%) 37 (21%) 
CFT subgroup 
      
<400 µm 58 302 (222–354) 245 (202–357) 0.353 23 (40%) 14 (24%) 0 (0%) 
≥400 µm 115 531 (462–674) 349 (245–467) <0.001 90 (78%) 73 (63%) 37 (32%) 
CFT = central foveal thickness, IQR = interquartile range.  
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Figure 1 | Change in a) central foveal thickness and b) central subfield thickness 12 months before and after fluocinolone 
intravitreal implant 
a) 
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b) 
 
Linear interpolation was used to impute missing values between CFT and CST scores. Nearest observation carried forward and backwards was then used to impute missing 
values prior to the first and after the last recorded measurement. Imputation was carried out in two parts, day -365 to day 0 and day 1 to 365. Individuals with no 
measurement prior to and post implant were excluded (n=60 for a) and n=52 for b).  
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Figure 2 | Cumulative frequency for central foveal thickness recorded at baseline and 12 months post FAc implant  
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Figure 3 | Central foveal thickness (CFT) at baseline and 12 months post implant  
a) Distribution of FAc treated eyes by CFT 
category at FAc implant and after 12 
months follow-up 
b) Distribution of FAc treated eyes achieving 
a CFT of ≤200 µm, >200 and ≤300 µm, 
>300 µm and ≤400 µm and >400 µm at 12 
months post implant by CFT at time of FAc 
implant 
  
c) CFT at FAc implant and after 12 months 
follow-up by CFT category at implant 
d) Change in CFT between FAc implant and 
12 months follow-up by CFT category at 
implant 
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Figure 4 | Visual acuity 12 months prior to and post FAc implant in study eyes a) with a central 
foveal thickness (CFT) <200 µm at FAc implant (N=12) and b) CFT ≥200 µm at FAc implant and 
<200 µm at 12 months post FAc implant (N=24) 
a) 
 
b) 
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Figure 5 | Correlates between central foveal thickness (CFT) and visual acuity 
a) Visual acuity and CFT at FAc implantation b) Visual acuity and CFT at 12 months post FAc 
implant 
  
c) All pairs of visual acuity and CFT 
measurements between 12 months prior to 
and 12 months post FAc implant 
d) Change in visual acuity and change in CFT 
between FAc implant and 12 month follow-up 
  
R = Pearson’s correlation coefficient, R2 = coefficient of determination. 
Only visual acuity and CFT measurements recorded on the same date were included. 
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Table 3 | Change in central subfield thickness  
 
N Baseline CST (µm) Post-index CST (µm) p-value ≥10% reduction in 
CST 
≥25% reduction in 
CST 
≥50% reduction in 
CST 
  
Median (IQR) Median (IQR) 
       
3 months 
            
Overall 155 448 (354–587) 356 (276–453) <0.001 83 (54%) 47 (30%) 13 (8%) 
CFT subgroup 
      
<400 µm 43 327 (269–377) 289 (257–343) 0.015 15 (35%) 5 (12%) 0 (0%) 
≥400 µm 99 503 (429–617) 382 (294–472) <0.001 61 (62%) 40 (40%) 13 (13%)              
6 months 
            
Overall 177 448 (359–581) 337 (268–445) <0.001 103 (58%) 62 (35%) 23 (13%) 
CFT subgroup 
      
<400 µm 51 327 (273–371) 291 (239–344) 0.012 19 (37%) 6 (12%) 0 (0%) 
≥400 µm 110 516 (436–622) 368 (274–460) <0.001 76 (69%) 53 (48%) 23 (21%)              
12 months 
            
Overall 181 446 (359–569) 318 (262–419) <0.001 118 (65%) 76 (42%) 25 (14%) 
CFT subgroup 
      
<400 µm 53 327 (281–371) 274 (251–333) 0.005 24 (45%) 10 (19%) 0 (0%) 
≥400 µm 112 516 (436–620) 337 (270–445) <0.001 86 (77%) 62 (55%) 25 (22%) 
CFT = central foveal thickness, CST = central subfield thickness, IQR = interquartile range. 
